Cargando…

Engineered human platelet-derived microparticles as natural vectors for targeted drug delivery

Drug targeting has opened a new paradigm in therapeutics with development of delivery vectors like liposomes and polymeric nanoparticles. Although their clinical application is crippled by limited biological adaptability. Off-target toxicity and biocompatibility still remains one of the critical pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kailashiya, Jyotsna, Gupta, Vineeta, Dash, Debabrata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791386/
https://www.ncbi.nlm.nih.gov/pubmed/31645903
http://dx.doi.org/10.18632/oncotarget.27223
_version_ 1783458971072331776
author Kailashiya, Jyotsna
Gupta, Vineeta
Dash, Debabrata
author_facet Kailashiya, Jyotsna
Gupta, Vineeta
Dash, Debabrata
author_sort Kailashiya, Jyotsna
collection PubMed
description Drug targeting has opened a new paradigm in therapeutics with development of delivery vectors like liposomes and polymeric nanoparticles. Although their clinical application is crippled by limited biological adaptability. Off-target toxicity and biocompatibility still remains one of the critical problems in anticancer therapeutics that can be life-threatening. Here we report a quick, simple and facile method of engineering human platelets to generate drug loaded platelet-derived microparticles (PMPs) by top-down approach, which are biocompatible and naturally target leukemia cells. Drug loaded PMPs and cancer cell uptake were characterized by flow cytometry, confocal microscopy, Nanoparticle Tracking Analysis and fluorimetry. Effective drug delivery was tested in cancer cell lines as well as in clinical samples from leukemia patients. We explored that PMPs are capable of carrying multiple drug payloads, have long shelf life and can be harvested in large quantity in short period. Importantly, PMPs exhibited remarkably higher toxicity towards cancer cells than free drug and had lower escape into extravascular spaces. Transfer of drug to cancer cells of leukemia patients was significantly higher than free drug, when delivered through PMPs. Our experiments validated therapeutic application of PMPs as biocompatible drug delivery vector against cancer cells with minimal off-target delivery.
format Online
Article
Text
id pubmed-6791386
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-67913862019-10-23 Engineered human platelet-derived microparticles as natural vectors for targeted drug delivery Kailashiya, Jyotsna Gupta, Vineeta Dash, Debabrata Oncotarget Research Paper Drug targeting has opened a new paradigm in therapeutics with development of delivery vectors like liposomes and polymeric nanoparticles. Although their clinical application is crippled by limited biological adaptability. Off-target toxicity and biocompatibility still remains one of the critical problems in anticancer therapeutics that can be life-threatening. Here we report a quick, simple and facile method of engineering human platelets to generate drug loaded platelet-derived microparticles (PMPs) by top-down approach, which are biocompatible and naturally target leukemia cells. Drug loaded PMPs and cancer cell uptake were characterized by flow cytometry, confocal microscopy, Nanoparticle Tracking Analysis and fluorimetry. Effective drug delivery was tested in cancer cell lines as well as in clinical samples from leukemia patients. We explored that PMPs are capable of carrying multiple drug payloads, have long shelf life and can be harvested in large quantity in short period. Importantly, PMPs exhibited remarkably higher toxicity towards cancer cells than free drug and had lower escape into extravascular spaces. Transfer of drug to cancer cells of leukemia patients was significantly higher than free drug, when delivered through PMPs. Our experiments validated therapeutic application of PMPs as biocompatible drug delivery vector against cancer cells with minimal off-target delivery. Impact Journals LLC 2019-10-08 /pmc/articles/PMC6791386/ /pubmed/31645903 http://dx.doi.org/10.18632/oncotarget.27223 Text en Copyright: © 2019 Kailashiya et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Kailashiya, Jyotsna
Gupta, Vineeta
Dash, Debabrata
Engineered human platelet-derived microparticles as natural vectors for targeted drug delivery
title Engineered human platelet-derived microparticles as natural vectors for targeted drug delivery
title_full Engineered human platelet-derived microparticles as natural vectors for targeted drug delivery
title_fullStr Engineered human platelet-derived microparticles as natural vectors for targeted drug delivery
title_full_unstemmed Engineered human platelet-derived microparticles as natural vectors for targeted drug delivery
title_short Engineered human platelet-derived microparticles as natural vectors for targeted drug delivery
title_sort engineered human platelet-derived microparticles as natural vectors for targeted drug delivery
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791386/
https://www.ncbi.nlm.nih.gov/pubmed/31645903
http://dx.doi.org/10.18632/oncotarget.27223
work_keys_str_mv AT kailashiyajyotsna engineeredhumanplateletderivedmicroparticlesasnaturalvectorsfortargeteddrugdelivery
AT guptavineeta engineeredhumanplateletderivedmicroparticlesasnaturalvectorsfortargeteddrugdelivery
AT dashdebabrata engineeredhumanplateletderivedmicroparticlesasnaturalvectorsfortargeteddrugdelivery